ONC leadership fills out with principal deputy national coordinator

Genevieve Morris has been named principal deputy national coordinator at the Office of the National Coordinator for Health IT (ONC).

Morris’ bio on the ONC site describes her as a “subject matter expert in health IT policy, program management, interoperability, meaningful use and the quality payment program (QPP).” In the new role, she’ll report directly to ONC chief Donald Rucker, MD.

Her most recent position was senior director for health IT policy at Baltimore-based Audacious Inquiry. She has helped on major ONC projects before, according to her bio, including developing the procedures and data related to health IT certification for meaningful use and its QPP equivalent, Advancing Care Information, and the health IT policies for the QPP’s Advanced Alternative Payment Models (APMs) track.

“The framework lays out a strategy for moving to more advanced health IT systems to enable APMs to be successful as they scale,” her ONC bio says.

While she was several years of health IT experience, Morris holds no medical or scientific degrees, unlike her predecessor, Vindell Washington, MD, who served in the deputy role before being promoted to ONC chief in August 2016. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.